All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On 27 November 2018, Clémentine Sarkozy from the University Hospital Center of Lyon, Lyon, FR, and colleagues, published in the Journal of Clinical Oncology a pooled analysis of French and US follicular lymphoma (FL) patients. The study evaluated the causes of death (CODs) in FL patients during the rituximab era.
FL is the most common indolent lymphoma subtype with lots of research having focused on treatment regimens and the pathology of the disease. There is a lack of data on the precise CODs in FL patients during the modern rituximab treatment era. The aim of this analysis was to contribute information on the exact reasons that FL patients die in France and the US, whilst on rituximab-based therapies.
This pooled analysis from French and American FL patients who were treated and diagnosed in the rituximab era, revealed that lymphoma was the main COD during the first ten years since diagnosis. Moreover, lymphoma-related mortality was the main COD irrespective of patient age and was significantly associated with FLIPI score. As expected, the cumulative risk of lymphoma-related death was higher in patients following FL transformation.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox